GlassScriptPhysician profile
Frank W Faris
NPI 1376644344
$14,269.39
in general payments reported to CMS, 2019-2025
36 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $979 · 2021: $1,699 · 2022: $1,876 · 2023: $3,059 · 2024: $2,825 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,380 · Gift: $162 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,379.94 |
| Gift | $161.50 |
| Education | $137.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,949.52 | 2019-2025 | |
| Janssen Biotech, INC. | $2,350.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Intra-Sana Laboratories | $2,074.01 | 2021-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $920.75 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $828.06 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Ferring Pharmaceuticals INC. | $473.57 | 2019-2024 | Rebyota |
| Braintree Laboratories, INC. | $434.40 | 2019-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $410.04 | 2019-2024 | Dificid, Zinplava |
| Genzyme Corporation | $404.79 | 2023-2025 | |
| Gilead Sciences, INC. | $369.61 | 2019-2025 | Livdelzi |
| Ironwood Pharmaceuticals, INC | $308.42 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $245.39 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $217.75 | 2020-2023 | |
| Pfizer INC. | $187.16 | 2019-2025 | |
| Enterra Medical, INC. | $165.93 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $161.47 | 2019 | |
| Celgene Corporation | $114.55 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $84.21 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $74.67 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $61.03 | 2024-2025 | Voquezna |
| Allergan, INC. | $50.86 | 2019-2020 | |
| Ucb, INC. | $46.26 | 2019 | |
| Lilly USA, LLC | $42.42 | 2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $36.57 | 2020-2023 | Terlivaz |
| Madrigal Pharmaceuticals | $34.99 | 2025 | Rezdiffra |
| Ardelyx, INC. | $30.99 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $22.01 | 2021 | |
| Novo Nordisk INC | $22.00 | 2025 | Wegovy |
| Alfasigma USA, INC. | $21.49 | 2020 | |
| Sun Pharmaceutical Industries INC. | $20.85 | 2021 | |
| Redhill Biopharma INC. | $20.54 | 2020 | |
| Concordia Pharmaceuticals INC. | $19.79 | 2019 | |
| Shire North American Group INC | $19.49 | 2019 | |
| Lucid Diagnostics INC. | $17.50 | 2024 | |
| Ethicon US, LLC | $13.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Faris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.